Summary Company Announcement Date: August 27, 2025 FDA Publish Date: August 27, 2025 Product Type: Drugs Reason for Announcement: Recall Reason Description Device & Drug Safety […]

[8/27/2025] FDA’s Center for Drug Evaluation and Research, Office of New Drugs has accepted a Letter of Intent for the qualification of Liver Stiffness Measurement by […]

Clozapine is an atypical antipsychotic medicine used to treat people who are severely ill with schizophrenia who remain symptomatic on other schizophrenia medicines. Clozapine is thought […]

[8-22-2025] The Food and Drug Administration is advising consumers not to purchase or use PAIN FLEX, a product promoted and sold for joint pain on various websites, […]

Citalopram (marketed as Celexa) is included in the class of drugs called selective serotonin reuptake inhibitors (SSRIs). This class of drugs is used to treat depression, anxiety, and other mood […]

Delivery Method: Via Email Product: Drugs Issuing Office: Center for Drug Evaluation and Research (CDER) United States WARNING LETTER July 29, 2025 RE: 711274 Dear AlzClipp: […]

CDER’s Office of Prescription Drug Promotion (OPDP)’s four-person research team investigates issues in direct-to-consumer and health care provider-directed prescription drug promotional communications. The team uses methodologies […]

Developing New Drugs American consumers benefit from having access to the safest and most advanced pharmaceutical system in the world. The main consumer watchdog in this […]

FDA has completed their review of the rationale document titled, “Isavuconazole Breakpoints for Aspergillus fumigatus” submitted by the Clinical and Laboratory Standards Institute (CLSI) to the […]